MX2022004270A - Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. - Google Patents

Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.

Info

Publication number
MX2022004270A
MX2022004270A MX2022004270A MX2022004270A MX2022004270A MX 2022004270 A MX2022004270 A MX 2022004270A MX 2022004270 A MX2022004270 A MX 2022004270A MX 2022004270 A MX2022004270 A MX 2022004270A MX 2022004270 A MX2022004270 A MX 2022004270A
Authority
MX
Mexico
Prior art keywords
reductase inhibitors
phosphomannomutase
deficiency
treatment
aldose reductase
Prior art date
Application number
MX2022004270A
Other languages
English (en)
Inventor
Shoshana Shendelman
Riccardo Perfetti
Original Assignee
Applied Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Therapeutics Inc filed Critical Applied Therapeutics Inc
Publication of MX2022004270A publication Critical patent/MX2022004270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La exposición se refiere a métodos para tratar PMM2-CDG utilizando inhibidores de aldosa reductasa.
MX2022004270A 2019-10-08 2020-10-07 Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. MX2022004270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912441P 2019-10-08 2019-10-08
PCT/US2020/054607 WO2021071965A1 (en) 2019-10-08 2020-10-07 Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency

Publications (1)

Publication Number Publication Date
MX2022004270A true MX2022004270A (es) 2022-05-03

Family

ID=75437528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004270A MX2022004270A (es) 2019-10-08 2020-10-07 Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.

Country Status (10)

Country Link
US (1) US20220226323A1 (es)
EP (1) EP4041219A4 (es)
JP (1) JP2022552831A (es)
CN (1) CN114667139A (es)
AU (1) AU2020363699A1 (es)
BR (1) BR112022005895A2 (es)
CA (1) CA3153108A1 (es)
IL (1) IL291946A (es)
MX (1) MX2022004270A (es)
WO (1) WO2021071965A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018307964B2 (en) 2017-07-28 2023-11-16 Applied Therapeutics Inc. Compositions and methods for treating galactosemia
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
WO2024064147A1 (en) * 2022-09-20 2024-03-28 Mayo Foundation For Medical Education And Research Treating congenital disorders of glycosylation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
IL283809B2 (en) * 2016-06-21 2024-01-01 Univ Columbia Compounds for use in a method for treating neuropathy, retinopathy, nephropathy or cardiomyopathy
AU2018307964B2 (en) * 2017-07-28 2023-11-16 Applied Therapeutics Inc. Compositions and methods for treating galactosemia
WO2020040831A1 (en) * 2018-08-20 2020-02-27 Perlara Pbc Methods for treating congenital disorders of glycosylation
BR112021019596A2 (pt) * 2019-04-01 2021-11-30 Applied Therapeutics Inc Inibidores de aldose redutase

Also Published As

Publication number Publication date
EP4041219A1 (en) 2022-08-17
BR112022005895A2 (pt) 2022-06-28
US20220226323A1 (en) 2022-07-21
EP4041219A4 (en) 2023-11-01
AU2020363699A1 (en) 2022-05-26
WO2021071965A1 (en) 2021-04-15
IL291946A (en) 2022-06-01
JP2022552831A (ja) 2022-12-20
CN114667139A (zh) 2022-06-24
CA3153108A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
AU2017382297A8 (en) Phosphodiesterase inhibitors and methods of microbial treatment
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EP4085919A3 (en) Compositions and methods to treat cancer
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
AU2018301696A8 (en) Heterocyclic inhibitors of ATR kinase
IL184678A0 (en) Proteasome inhibitors and methods of using the same
MX2021010916A (es) Inhibidores rad51.
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
MX2020000367A (es) Inhibidores de rad51.
MX2022009366A (es) Compuestos y usos de estos.
AU2020258568A8 (en) CD73 inhibitors
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2023013912A (es) Metodos para inhibir ras.
PH12019500479A1 (en) Compositions for treating dementia
ZA202106519B (en) Caspase inhibitors and methods of use thereof
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2019010060A (es) Composiciones y metodo para tratar cancer.